Story perspectives

KRAS Vaccine Prevents Pancreatic Cancer, Cuts Cysts 37%

7/17/2026

Summary

Story summary

Johns Hopkins researchers gave the experimental mKRAS-VAX vaccine to 20 high-risk participants.
Injections were given subcutaneously at weeks 1, 3, 5 and a boost at week 13, causing only mild injection-site or flu-like symptoms.
KRAS-specific effector and central memory T-cell responses were detected in 18 of 20 participants and lasted up to two years.
After a median 16.5-month follow-up, none developed pancreatic cancer and 37.5 % showed cyst reduction versus 6.8 % in an unvaccinated group.

1 of 1

Story summary

Johns Hopkins researchers gave the experimental mKRAS-VAX vaccine to 20 high-risk participants.
Injections were given subcutaneously at weeks 1, 3, 5 and a boost at week 13, causing only mild injection-site or flu-like symptoms.
KRAS-specific effector and central memory T-cell responses were detected in 18 of 20 participants and lasted up to two years.
After a median 16.5-month follow-up, none developed pancreatic cancer and 37.5 % showed cyst reduction versus 6.8 % in an unvaccinated group.